AMR Kansas City Oncology

Merriam, KS
Website
(888) 803-1766

Sorting 1 by

Accepting patients

GLB-001

A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Learn more
  • Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
  • High Risk
  • Phase 1
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials